


CLM-PTO

April 21, 2005

Claims 1-24 are canceled.

25. A compound represented by C_6H_{12} is



۲۷۷

प्राचीन भारतीय

W represents CH_2 , O, or NR;

X represents S or O;

Y represents CR, or %;

R represents H or alkyl.

R' represents H, alkyl, or halogen;

R. compressa H. et al.

R₂ represents a methyl or heteroaryl;

R. capistratus Horváth

Reconnection by a loop

Reprinted from *Refugee*;

R₁ and K₂ may be connected

P_1 and P_2 may be connected

R_1 and R_2 may be connected through a correlation

policy; and

R_2 and R_3 may be connected through a covalent bond; or $\text{N}(R_2)(R_3)$ represents 4-aminoyl; and

the stereochemical configuration at a stereocenter in a compound represented by C is R, S, or a mixture thereof.

Art Unit: 1700

- 26. The compound of claim 25, wherein X represents S.
- 27. The compound of claim 25, wherein Y represents CR'.
- 28. The compound of claim 25, wherein W represents CH₂ or O.
- 29. The compound of claim 25, wherein n is 1 or 2; and p is 2.
- 30. The compound of claim 25, wherein R' represents H.
- 31. The compound of claim 25, wherein R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, or 5-chlorobenzo[b]thiophen-3-yl.
- 32. The compound of claim 25, wherein X represents S; and Y represents CR'.
- 33. The compound of claim 25, wherein X represents S; Y represents CR'; and W represents CH₂ or O.
- 34. The compound of claim 25, wherein X represents S; Y represents CR'; W represents CH₂ or O; n is 1 or 2; and p is 2.
- 35. The compound of claim 25, wherein X represents S; Y represents CR'; W represents CH₂ or O; n is 1 or 2; p is 2; and R' represents H.
- 36. The compound of claim 25, wherein X represents S; Y represents CR'; W represents CH₂ or O; n is 1 or 2; p is 2; R' represents H; and R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, or 5-chlorobenzo[b]thiophen-3-yl.

Claims 37-44 are canceled.

Art Unit: 1700

45. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

46. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

47. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

48. [REDACTED] The compound of claim 1, 17, 25, or 37, wherein said compound has an EC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

49. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

50. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

51. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

52. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

53. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

54. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

55. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

55. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

56. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

57. The compound of claim 1, 17, 25, or 37, wherein said compound is a single stereoisomer.

58. A formulation, comprising a compound of claim 1, 17, 25, or 37; and a pharmaceutically acceptable excipient.

Claims 59-106 are canceled.